Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rheumatic syndromes associated with malignancy.

Eliza Chakravarty1, Mark C Genovese

  • 1Department of Medicine, Stanford University, Palo Alto 94304, USA.

Current Opinion in Rheumatology
|December 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.

The lancet. Gastroenterology & hepatology·2025
Same author

Risk of preterm delivery and early pregnancy hydroxychloroquine use from a Californian lupus cohort.

Lupus science & medicine·2025
Same author

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.

RMD open·2025
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Rheumatic syndromes and malignancy share complex links due to immune system dysfunction. Recognizing these associations aids diagnosis, treatment, and surveillance for both conditions.

Area of Science:

  • Rheumatology
  • Oncology
  • Immunology

Background:

  • Rheumatic diseases and malignancy exhibit a complex bidirectional relationship.
  • Autoimmunity, aberrant immune responses, and immunomodulatory drugs contribute to this association.
  • Malignancy can manifest with rheumatic disease features, and rheumatic diseases may increase cancer risk.

Purpose of the Study:

  • To elucidate the intricate connections between rheumatic syndromes and underlying malignancies.
  • To highlight the diagnostic and therapeutic implications of these associations for clinicians.
  • To emphasize the importance of surveillance for complications arising from this interplay.

Main Methods:

  • Review of existing literature on rheumatic syndromes and malignancy.

Related Experiment Videos

  • Analysis of etiological factors, including autoimmunity and immune dysregulation.
  • Clinical case study analysis (implied).

    • Main Results:

    • Rheumatic diseases can increase the risk of developing malignancy.
    • Malignancy can present with symptoms mimicking rheumatic diseases.
    • Shared underlying mechanisms, such as immune system alterations, are implicated.

    Conclusions:

    • Awareness of the rheumatic syndromes-malignancy link is crucial for accurate diagnosis.
    • Effective management requires addressing both rheumatic symptoms and the underlying malignancy.
    • Appropriate surveillance strategies are essential for managing patients with these overlapping conditions.